Gustavo Alva, MD, DFAPA

Gus Alva, MD, DFAPA, joins Erin Crown to discuss how regional meetings, industry exchange, and emerging treatments can help clinicians avoid burnout and better serve patients.

Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.

Closing the discussion, the panel offers practical guidance on patient education, ongoing clinical learning, and community-based research opportunities to help clinicians move schizophrenia care forward.

Caregivers carry an enormous, often invisible burden in schizophrenia care. The panel discusses how curiosity, communication, and community resources can support families while helping patients hold onto hope.

Most patients with schizophrenia never work, drive, or build a full independent life. The panel argues that celebrating small victories and raising expectations can meaningfully change that trajectory.

Beyond dopamine, new mechanisms targeting inflammation and glutamatergic pathways are reshaping the schizophrenia pipeline. The panel discusses which emerging agents hold the most promise for patients.

Clinics must adapt to REMS-style models as esketamine teaches supervision and reimbursement lessons ahead of psilocybin’s potential FDA clearance.

Psychedelic trials may face blinding failures; concerns around FDA safeguards, active comparators, and filmed sessions.

Psychedelic psychiatry gains momentum as clinicians weigh evidence, safety, and stigma.

Real-world results and a personal caregiver's story build the case for starting a muscarinic agonist earlier, even at first break, rather than waiting until other options are exhausted.

A newly approved muscarinic agonist offers a genuinely different mechanism for treating schizophrenia. The panel explains how it works and why most are choosing to add it rather than switch.

Deciding when and how to change a schizophrenia treatment plan requires curiosity, comparative evidence, and careful sequencing. The panel discusses long-acting injectables, combination strategies, and when clozapine becomes the right next step.

From long-acting injectables to rational combination therapy, the panel maps today's treatment landscape, weighing efficacy against adverse events and stressing the

Being out of the hospital is not the same as being well. The panel makes the case for measurement-based care and more ambitious, individualized treatment goals for patients living with schizophrenia.

Negative and cognitive symptoms shape daily functioning far more than clinicians often recognize. The panel discusses building trust, using structured tools, and addressing tardive dyskinesia to close a persistent care gap.

A detailed case study reveals how positive, negative, and cognitive symptoms can persist for years even when a patient appears clinically stable, challenging the panel to define what genuine functional recovery should look like.

Despite effective treatments, most patients with schizophrenia go undertreated. The panel examines how stigma, fear, and outdated expectations for recovery continue to limit both patients and the clinicians who treat them.

STARS experts redefine stuttering as a brain-based neuropsychiatric disorder, urging interdisciplinary care and warning dopamine-boosting ADHD or antidepressant meds may worsen symptoms.

Learn how experts distinguish agitation from psychosis in Alzheimer disease, weigh new FDA options, and apply evidence for off-label care.

Clinicians outline ways to boost schizophrenia outcomes: team-and-family collaboration, early detection, medication access, measurement-based care.

New rapid-acting and long-acting injectables help bridge hospital-to-community care, cutting post-discharge nonadherence and relapse risk.

Clinicians weigh telepsychiatry for schizophrenia, urge early long-acting injectables, and reveal tips on samples, coupons, and prior authorizations.

Inside the ED psychiatric crisis pathway: rapid evaluation, safety triage, long-acting injectables,

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

Discover how coordinated schizophrenia care teams—clinicians, social supports, and peers—improve communication, housing, work, and quality of life.

Where can vagus nerve stimulation fit into treating depression?

Clinicians track relapse risk in schizophrenia by spotting functional decline, paranoia, missed care, and triggers, using family check-ins, brief scales, and labs.

Phase 3 COMP360 psilocybin data show lasting TRD relief; experts explain brain-network reset, therapy support, and what approval could mean.

Therapeutic drug monitoring clarifies adherence and plasma levels, while long-acting injectables and patches reduce variability and support patient-centered benefit-risk decisions.

Clinicians weigh oral, LAI and transdermal antipsychotics, urging early use, adherence focus, and side-effect education to optimize outcomes.